NXC-201 CAR-T

NXC-201 CAR-T (NXC-201, HBI0101) is a CAR-T cell therapy developed by Nexcella. Its target is BCMA. The sponsor states: Autologous T cells transduced ex vivo with an anti-BCMA CAR retroviral vector, provided fresh without cryopreservation. ClinicalTrials.gov describes the intervention as: NXC-201 (formerly HBI0101) CAR-T is defined as autologous T cells transduced ex-vivo with anti-BCMA CAR retroviral vector encoding the chimeric antigen receptor (CAR) targeted to human BCMA. The NXC-201 CAR-T is provided fresh without cryop. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial. The largest, NCT06097832, plans to enrol 45 participants with primary completion expected 2026-12. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.